Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 July 2025
Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit führenden Neuroimaging-Gruppe
Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS)....
8 July 2025
Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...
9 July 2025
Filter & Suche
Fondsstrategie :
Loading...
Das waren alles Artikel
d96bd52a70